Efficacy assessed in follow-ups of clinical trials: methodological conundrum by Landewé, Robert BM
Long-term follow-ups of randomised clinical trials are a 
contradictio in terminis.
With this rather bold statement I do not mean that 
such studies are impossible to conduct. Rantalaiho and 
colleagues have proven with the publication of the 
11-year follow up of their world-famous Fin-RACo trial 
that dedicated investigators and patients who believe in 
the goals of the study can create a dataset that is 
insurmountable in terms of wealth, from which we can 
learn a lot about the long-term fate of patients with 
rheumatoid arthritis (RA) [1]. Th   e authors have carefully 
analysed the available radiographic data, they have 
investigated important long-term outcomes such as 
mortality and joint-replacement surgery, and they have 
appropriately modelled longitudinal data. Th  eir conclu-
sion that early aggressive therapy with combinations of 
conventional disease-modifying antirheumatic drugs 
including corticosteroids pays oﬀ   in terms of long-term 
radiographic and clinical beneﬁ  ts is credible. And their 
argument that ‘treat to target’ is the best way to exploit 
those beneﬁ  ts is convincing [1].
What concerns me most in Rantalaiho and colleagues’ 
interpretation – and admittedly in similar exercises in 
which I took part myself [2,3] – is the implicit assumption 
that two groups of patients formed a decade ago by a 
stochastic process that we call randomisation can be 
compared 11 years later under the same premise of 
prognostic similarity.
Groups in randomised clinical trials (RCTs) may violate 
prognostic similarity even at baseline. Chance theory 
tells us that if we were to perform the procedure of 
randomisation 1,000 times, we may face a number of 
attempts with a number of imbalances, sometimes even 
in prognostically relevant variables. We usually ignore 
such baseline diﬀ  erences, assuming that imbalances may 
occur in either direction, and their combined net eﬀ  ect 
on the outcome of interest is probably negligible. Th  e 
important consideration is that these baseline diﬀ  erences 
are completely by chance (random), which means ‘not 
driven by any tangible or impressionable process’.
I need this piece of theory to convince you that 
Rantalaiho and colleagues’ 11-year-old RCT follow-up 
has suﬀ   ered from many inﬂ   uences that may have 
jeopardised prognostic similarity. Let us look through the 
spectacles of the trial methodologist and play devil’s 
advocate by working out two important biases: con  foun-
ding by indication and confounding by trial completion.
Th   e Fin-RACo trial had a protocol for only 2 years [4], 
implying that any treatment choice thereafter was up to 
the discretion of the doctor and the patient. Undoubtedly, 
the physician wanted the best for the patient, thus 
prioritising the patient’s wellbeing over the fate of the 
study. A consequence of good clinical practice, however, 
is that – as conﬁ  rmed by Rantalaiho and colleagues – the 
worst patients may have received the most intensive 
(eﬀ   ective, costly) treatment, which may in turn have 
unquantiﬁ  able inﬂ  uences on the outcome of interest. If 
such events occur in an unbalanced fashion, we speak 
about confounding by indication. I think in RA, with its 
many eﬀ  ective treatments to choose and its inextricable 
relationship between disease activity (determinant) and 
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foun  ding by indication should be a number-one reason to 
refrain from statistical between-group comparisons in 
long-term follow-ups of RCTs.
Th  e second issue is related to the ﬁ  rst, but is slightly 
diﬀ   erent in nature: confounding by trial completion. 
Obviously, the investigators have done their best in 
obtaining the outcome of interest in as many patients as 
possible. Expectedly, they have not been able to assess 
outcome in every patient. What is important from a 
methodological point of view is whether this loss to 
follow-up was completely random. Usually it is impos-
sible to determine the exact reasons for patients not 
showing up at a control visit or an end-of-study assess-
ment. Usually, therefore, it is impossible to conclude that 
a no-show (or missing) had nothing to do with the 
severity and activity of the RA. What follows is that you 
cannot be sure that such events are distributed evenly 
across trial groups, and therefore every between-group 
comparison under the assumption of prognostic 
similarity is meaningless. Rantalaiho and colleagues have 
done their best to collect as many radiographs from as 
many patients as possible, but – not unexpectedly – more 
than 30% of the patients miss their 11-year radiographic 
assessment. Th   e investigators may, like many authors do, 
provide inferential arguments that drop-out is not 
relevant in their study, but unfortunately one cannot 
judge.
Th   ese two biases mean I am rather reluctant to accept 
ﬁ  rm conclusions from follow-ups of RCTs that have been 
analysed a decade after the randomisation procedure, 
however credible they may seem. Many events may have 
occurred in every individual patient in the trial that may 
have broken prognostic similarity. I therefore do not truly 
believe in the explanation of diﬀ  erences after 10 years of 
intangibly trying to inﬂ  uence patients’ fates.
Does this make Rantalaiho and colleagues’ results 
useless? Absolutely not. We welcome cohorts of patients 
that have been followed for years in order to ﬁ  nd out 
what eventually determines the disease course. Ideally 
such cohorts include patients with severe and less severe 
disease, with more and less active RA, with more and less 
aggressive initial treatment. We should know a lot more 
about these patients’ fates; their baseline values and their 
baseline biomaterials are extremely important in deﬁ  ning 
new prognostic biomarkers. Such carefully conducted 
studies may give insight into what is really important in 
determining an individual patient’s prognosis in a world 
full of treatment choices that diﬀ   er in eﬃ   cacy, 
eﬀ  ectiveness and cost.
Explained in terms of contradictio in terminis,  the 
contradiction is in the recognition that the randomised 
part of a RCT is not necessarily a licence for harmlessly 
comparing treatment eﬀ  ects after a decade of follow-up 
of that trial.
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